Alpha Tau Medical Ltd. announced the completion of enrollment of 88 patients in its ReSTART pivotal trial for treating recurrent cutaneous squamous cell carcinoma (cSCC) with Alpha DaRT®. This marks the company's first completed U.S. pivotal study and a critical milestone toward FDA pre-market approval. The company has already initiated a modular PMA application process. Alpha DaRT has received Breakthrough Device Designation from the FDA for this indication.

Alpha Tau Medical will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026, discussing recent achievements and upcoming data milestones for their Alpha DaRT cancer therapy.

The global radiopharmaceuticals market is projected to grow at a CAGR of 10.3% from 2024 to 2030, driven by the increasing prevalence of chronic diseases, advancements in imaging technology, and the transition towards personalized medicine. North America and Asia-Pacific are the key regional markets.

Alpha Tau Medical Ltd. announced the appointment of Maya Netser to its Board of Directors, while Meir Jakobsohn is stepping down from the Board but will continue to serve as an advisor.

TIMB, AKYA, DRTS, TRUP and QSG have been added to the Zacks Rank #1 (Strong Buy) List on January 8, 2024.

Alpha Tau Medical (NASDAQ:DRTS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 0 0 0 In the last 3 months, 4 analysts have offered 12-month price targets for Alpha Tau Medical. The company ...Full story available on Benzinga.com

Alpha Tau Medical Ltd. (DRTS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Within the last quarter, Alpha Tau Medical (NASDAQ:DRTS) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 1 1 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Alpha Tau Medical has ...Full story available on Benzinga.com

Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) rose 62.4% to $3.15 in pre-market trading after falling 11% on Monday. Tivic Health Systems inked a pact to make its products available on AmerisourceBergen’s third-party marketplace. Shineco, Inc. (NASDAQ: SISI) shares gained 50% to $0.2130 in pre-market trading after declining over 3% on Monday. noco-noco Inc. (NASDAQ: NCNC) shares rose 44.5% to $2.89 in pre-market trading after falling 23% on Monday. Caravelle International Group (NASDAQ: CACO) shares climbed 26.5% to $0.7087 in pre-market trading after falling 11% on Monday. iCoreConnect Inc. (NASDAQ: ICCT) shares gained 23.8% to $1.97 in pre-market trading after dipping 20% on Monday. Bright Scholar Education Holdings Limited (NYSE: BEDU) shares rose 14.7% to $1.01 in pre-market trading. Bright Scholar Education recently announced its unaudited financial results for ...

Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect an improvement at the Animal Health segment.

Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.

Alpha Tau Medical (DRTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.